Objective:
The objective of this study was to assess the long-term efficacy and safety of plasma kinetic vaporization (PKVP) of the prostate for symptomatic benign prostatic hyperplasia.
Patients and Methods:
Twenty-one patients had been enrolled in this study at Al-Azhar University Hospitals to evaluate their long-term follow-up after PKVP. The outcome was evaluated using the International Prostate Symptom Score (IPSS), quality of life (QOL), peak urinary flow rate (Q
max
), postvoiding residual (PVR) of urine, prostate volume, prostate-specific antigen (PSA) level, and long-term complications of the surgery.
Results:
Preoperatively, IPSS was 22.14 ± 2.22, QOL score was 4.90 ± 0.54, Q
max
was 8.97 ± 2.49 ml/s, PVR was 138.5 ± 56.5 ml, prostate volume was 64.32 ± 11.16 ml, and PSA level was 4.18 ± 1.95 ng/ml. Two years’ post-PKVP, IPSS decreased to 8.57 ± 5.55, QOL score decreased to 1.90 ± 1.22, Q
max
increased to 17.17 ± 7.91 ml/s, PVR decreased to 38.81 ± 59.54 ml, prostate volume decreased to 22.45 ± 7.22 ml, and PSA level decreased to 1.59 ± 0.74 ng/ml. One patient (4.8%) developed bulbar urethral stricture, 1 (4.8%) developed bladder neck contracture, and 1 (4.8%) developed meatal stenosis. Erectile dysfunction was reported by two out of 12 patients who were sexually potent before surgery, and retrograde ejaculation was reported by 10 patients (83%).
Conclusion:
The present study has demonstrated satisfactory good efficacy and safety of PKVP on the long term.